We use cookies for a better user experience. Read our Privacy Policy

I Agree

Gonorrhea Therapeutics Market

Gonorrhea Therapeutics Market (Gonococcal Infection: Uncomplicated Gonococcal Infection, Gonococcal Arthritis, Gonococcal Meningitis, and Endocarditis; Treatment: Monotherapy and Dual Therapy; Route of Administration: Oral and Injectable; Gender: Women and Men; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Gonorrhea Therapeutics Market - High Scope of Advancement with Curative Approach

Improved sensitivity of early diagnostic screening tools has highlighted grave concerns regarding the surge in gonorrhea incidences. As per a survey conducted by the Centers for Disease Control and Prevention, 555,608 cases of gonorrhea were reported in 2017, in the U.S., demonstrating an increase of 18.6% from 2009. These figures have hard-pressed the governments of numerous countries to take preventive and curative measures for relegating the prevalence of gonorrhea.

According to the gonorrhea therapeutics market research report published by Transparency Market Research (TMR), women are more susceptible to this disease than men, and the number of women availing therapeutics is on an exponential increase, thereby making women the key demographic of the market. The scramble of market players towards addressing the issue at the grass-root level has engendered several vaccines, including 4CMenB and rLP2086, which harbingers steady growth prospects for the landscape. However, literatures claiming the progressive resistance of gonorrhea to therapeutics could surface uncertainties regarding market advancement.

gonorrhea therapeutics market infographic

To know the scope of our report Get a Sample on Gonorrhea Therapeutics Market

'Women More Susceptible to Gonorrhea than Men', finds TMR Study

The connection of gonorrhea with infertility has accelerated the pace of research & development activities among market players to introduce effective therapeutics to combat this public health threat. A research team at the Louisiana State University Health Sciences discovered a novel antibiotic - zoliflodacin - to inhibit bacteria’s DNA synthesis with a differentiated approach than current antibiotics, which was well-received by the FDA, and the same has been marketed as an oral treatment for gonorrhea. Besides oral drugs, medical personnel recommend dual therapy over monotherapy, given the growing resistance of Neisseria Gonorrhoeae to antibiotics.

A majority of women with gonorrhea show subtle signs of ongoing damage to the uterine tract, which, if left untreated, could cause involuntary infertility, ectopic pregnancy, or even chronic pelvic pain. As a result, this TMR study identifies that, the number of women availing gonorrhea therapeutics is projected to rise at a CAGR of ~6% during 2019-2027, with uncomplicated gonococcal infection being the leading cause.

Get a glimpse of the in-depth analysis through our Report Brochure

Why Partnerships with Hospital Pharmacies Could be Profitable

The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain preferred care centers for patients diagnosed with gonorrhea. According to TMR’s estimates, hospital pharmacies will account for a value tantamount to ~US$ 548 Mn in 2019, out of which, ~37% of sales will come from hospital pharmacies based in North America alone.

Propitious environment for the growth of the healthcare sector in North America that is attributable to the intervention of the government in creating awareness regarding the prevalence of diseases, and hefty financial allocations for R&D activities are also likely to reflect on the advancement of the gonorrhea therapeutics market. Currently, North America monopolizes the gonorrhea therapeutics market; however, the Asia Pacific market holds profitable prospects on account of the growing sprawl of bacterial infections. On top of it, improvements in healthcare infrastructure coupled with financial lucidity of individuals has encouraged a large base to opt for effective gonorrhea therapeutics.

gonorrhea therapeutics market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Authors of the report opine that, the gonorrhea therapeutics market will rise from ~US$ 1.4 Bn in 2019 to ~US$ 2 Bn in 2027, representing a CAGR of ~5% during the forecast period, with the shifting paradigm from a preventive to curative healthcare approach. A heated competitive landscape in the global pharmaceutical vicinity is encouraging market players to penetrate into new markets to channelize the supply of therapeutics and consolidate their market position.

However, the same is not achieved only by forward integration but also by inorganic practices such as acquisitions, mergers, and collaborations, in order to establish distribution partnerships with regional and local players. For instance, AstraZeneca announced the acquisition of Takeda Pharmaceutical Company Limited to expand in regions with high growth potential. To add to that, market players can prioritize investments towards the development of vaccines to infiltrate into the market with a curative approach

Gonorrhea Therapeutics Market: Overview

  • The global gonorrhea therapeutics market is projected to be valued at ~US$ 1.4 Bn in 2019, and expand at a CAGR of ~5.3% from 2019 to 2027. The rising prevalence of the disease and increasing use of new diagnostic tests are key factors that fuel the global gonorrhea therapeutics market.
  • Gonorrhea is a sexually transmitted infection caused by a bacterium, and can be transmitted through sexual contact. All people who are sexually active may be at the risk of acquiring gonorrhea. Gonorrhea can infect the urethra (the tube that allows urine and semen to pass out of the body), cervix, rectum, throat, mouth, and eyes. Though, several people suffering from gonorrhea do not exhibit any symptoms.
  • If symptoms do occur, they usually appear one to seven days after an infection. Symptoms can include vaginal pain, painful urination, and an abnormal discharge from the vagina, urethra, or rectum. Gonorrhea tests include obtaining samples from the sites of suspected infection and testing for the presence of the bacteria.
  • Gonorrhea can be treated and cured using antibiotics; however, some strains of gonorrhea have become resistant to a few antibiotics. Gonorrhea can increase the risk of the sexual transmission of HIV.
  • Gonorrhea can be transmitted through sexual intercourse. Transmission occurs when secretions from infected mucous membranes or semen of a person with a urethral infection come into contact with the mucous membranes of another person. Condom-less penetrative vaginal sex and anal sex are significantly high risk behaviors for the transmission of gonorrhea. Gonorrhea can be transmitted when a person who has an infection in the mouth or throat performs oral sex on another person, or when a person performs oral sex on a person who has a genital infection.

Global Gonorrhea Therapeutics Market: Drivers & Restraints

  • Rising Prevalence of Gonorrhea: Gonorrhea is the second-most commonly reported notifiable disease in the U.S. Infections due to Neisseria gonorrhea, such as those resulting from Chlamydia trachomatis, are a major cause of pelvic inflammatory disease (PID) in the U.S. Moreover, epidemiologic and biologic studies provide evidence that gonococcal infections facilitate the transmission of HIV infection.
  • Emergence of Antibiotic-Resistant Gonococcal Strain: CDC data highlights the rising resistance to one of the two antibiotics in the dual therapy for gonorrhea, a development that threatens the last remaining effective treatment for the disease. N. gonorrhea has progressively developed resistance to each of the antimicrobials used for the treatment of gonorrhea. Declining susceptibility to cefixime resulted in a change to the CDC treatment guidelines in 2015, so that dual therapy with ceftriaxone and azithromycin is presently the only CDC recommended treatment regimen for gonorrhea.

Global Gonorrhea Therapeutics Market: Segment Analysis

  • The global gonorrhea therapeutics market has been segmented based on gonococcal infection, treatment, route of administration, gender, distribution channel and region
  • In terms of gonococcal infection, the global gonorrhea therapeutics market has been classified into uncomplicated gonococcal infection, gonococcal arthritis, gonococcal meningitis, and endocarditis. In terms of treatment, the global gonorrhea therapeutics market has been classified into monotherapy and dual therapy. In terms of route of administration, the global gonorrhea therapeutics market has been classified into oral and injectable. In terms of gender, the global gonorrhea therapeutics market has been bifurcated into women and men.
  • The uncomplicated gonococcal infection segment is projected to dominate the gonorrhea therapeutics market by the end of 2019. It is projected to maintain its dominance during the forecast period too.
  • Based on distribution channel, the global gonorrhea therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment is estimated to dominate the gonorrhea therapeutics market by the end of 2019.

Global Gonorrhea Therapeutics Market: Regional Segmentation

  • In terms of region, the global gonorrhea therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America
    • North America dominated the global gonorrhea therapeutics market in 2018 due to the growing prevalence of STDs and rapid advances in healthcare infrastructure in the region.
    • According to a recent study by the World Health Organization, in the U.S. alone, ~1 million cases of gonorrhea are reported annually. Favorable reimbursement policies and government funding to numerous health organizations for the development of drug-resistant gonorrhea treatment are projected to remain the key drivers of the gonorrhea therapeutics market in the region.
  • Europe
    • The gonorrhea therapeutics market in Europe is anticipated to expand at a considerable growth rate in the near future, owing to the increasing incidence of gonococcal infection in the region. Gonorrhea is the second-most notified sexually transmitted infection in Europe, after chlamydia.
  • Asia Pacific
    • The gonorrhea therapeutics market in Asia Pacific is projected to expand at a notable CAGR during the forecast period, due to a large patient pool and rise in investments in healthcare in countries such as China in the region.

Global Gonorrhea Therapeutics Market: Major Players

  • Key players operating in the global gonorrhea therapeutics market include
    • GlaxoSmithKline plc.
    • Merck & Co., Inc.
    • Pfizer Inc
    • AstraZeneca
    • Hologic, Inc.
    • Danaher
    • Abbott
    • Becton Dickinson and Company
    • F. Hoffmann-La Roche Ltd.
  • These players are adopting strategies such as new product development, partnerships, and acquisitions to remain competitive in the global gonorrhea therapeutics market.

Gonorrhea Therapeutics Market - Segmentation

In order to present an incisive view of the gonorrhea therapeutics market, analysts and researchers of the report have segregated the gonorrhea therapeutics market based on the gonococcal infection, treatment, route of administration, gender, distribution channel, and region. This comprehensive business study also analyzes the incremental opportunity present in the gonorrhea therapeutics market during the forecast period. The key segments of the gonorrhea therapeutics market are as mentioned below:

Gonococcal Infection

Uncomplicated Gonococcal Infection

Gonococcal Arthritis

Gonococcal Meningitis and Endocarditis

Treatment

Monotherapy

Dual Therapy

Route of Administration

Oral

Injectable

Gender

Women

Men

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

 

Gonorrhea Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of gonorrhea therapeutics market?

Gonorrhea therapeutics market to reach a valuation of ~US$ 2 Bn by 2027

What is the anticipated CAGR of the gonorrhea therapeutics market in the forecast period?

Gonorrhea therapeutics market to expand at a CAGR of ~5.3% from 2019 to 2027

What are the key driving factors for the growth of the gonorrhea therapeutics market?

Gonorrhea therapeutics market is driven by rising prevalence of gonorrhea and use of new diagnostic tests

Which region is expected to project the highest market share in the global gonorrhea therapeutics market?

North America accounted for a major share of the global gonorrhea therapeutics market

Who are the key players in the gonorrhea therapeutics market?

Key players in the global gonorrhea therapeutics market include GlaxoSmithKline plc. Merck & Co., Inc., Pfizer Inc, AstraZeneca, Hologic, Inc., Danaher

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gonorrhea Therapeutics Market 

4. Market Overview

    4.1. Introduction

        4.1.1. Gonococcal Infection Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Gonorrhea Therapeutics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Regulatory Scenario by Region/globally

    5.2. Reimbursement Scenario by Region/globally

6. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gonococcal Infection Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

        6.3.1. Uncomplicated Gonococcal Infection

        6.3.2. Gonococcal Arthritis

        6.3.3. Gonococcal Meningitis and Endocarditis

    6.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gonococcal Infection Type

7. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Treatment

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

        7.3.1. Monotherapy

        7.3.2. Dual Therapy

    7.4. Global Gonorrhea Therapeutics Market Attractiveness, by Treatment

8. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

        8.3.1. Oral

        8.3.2. Injectable

    8.4. Global Gonorrhea Therapeutics Market Attractiveness, by Route of Administration

9. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gender

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Global Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

        9.3.1. Women

        9.3.2. Men

    9.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gender

10.  Global Gonorrhea Therapeutics Market Analysis and Forecast, by Distribution Channel

    10.1. Introduction & Definition

    10.2. Key Findings / Developments

    10.3. Global Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

        10.3.4. Others

    10.4. Global Gonorrhea Therapeutics Market Attractiveness, by Distribution Channel

11. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Region

    11.1. Key Findings

    11.2. Global Gonorrhea Therapeutics Market Forecast, by Region

        11.2.1. North America

        11.2.2. Europe

        11.2.3. Asia Pacific 

        11.2.4. Latin America

        11.2.5. Middle East & Africa

    11.3. Global Gonorrhea Therapeutics Market Attractiveness, by Region

12. North America Gonorrhea Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. North America Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

        12.2.1. Uncomplicated Gonococcal Infection

        12.2.2. Gonococcal Arthritis

        12.2.3. Gonococcal Meningitis and Endocarditis

    12.3. North America Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

        12.3.1. Monotherapy

        12.3.2. Dual Therapy

    12.4. North America Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

        12.4.1. Oral

        12.4.2. Injectable

    12.5. North America Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

        12.5.1. Women

        12.5.2. Men

    12.6. North America Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

        12.6.1. Hospital Pharmacies

        12.6.2. Retail Pharmacies

        12.6.3. Online Pharmacies

        12.6.4. Others

    12.7. North America Gonorrhea Therapeutics Market Forecast, by Country, 2017–2027

        12.7.1. U.S.

        12.7.2. Canada

    12.8. North America Gonorrhea Therapeutics Market Attractiveness Analysis 

        12.8.1. By Gonococcal Infection Type

        12.8.2. By Treatment 

        12.8.3. By Route of Administration

        12.8.4. By Gender

        12.8.5. By Distribution Channel

        12.8.6. By Country

13. Europe Gonorrhea Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Europe Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

        13.2.1. Uncomplicated Gonococcal Infection

        13.2.2. Gonococcal Arthritis

        13.2.3. Gonococcal Meningitis and Endocarditis

    13.3. Europe Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

        13.3.1. Monotherapy

        13.3.2. Dual Therapy

    13.4. Europe Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

        13.4.1. Oral

        13.4.2. Injectable

    13.5. Europe Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

        13.5.1. Women

        13.5.2. Men

    13.6. Europe Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

        13.6.1. Hospital Pharmacies

        13.6.2. Retail Pharmacies

        13.6.3. Online Pharmacies

        13.6.4. Others

    13.7. Europe Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027

        13.7.1. Germany

        13.7.2. U.K.

        13.7.3. France

        13.7.4. Spain

        13.7.5. Italy

        13.7.6. Rest of Europe

    13.8. Europe Gonorrhea Therapeutics Market Attractiveness Analysis 

        13.8.1. By Gonococcal Infection Type

        13.8.2. By Treatment 

        13.8.3. By Route of Administration

        13.8.4. By Gender

        13.8.5. By Distribution Channel

        13.8.6. By Country

14. Asia Pacific Gonorrhea Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

        14.2.1. Uncomplicated Gonococcal Infection

        14.2.2. Gonococcal Arthritis

        14.2.3. Gonococcal Meningitis and Endocarditis

    14.3. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

        14.3.1. Monotherapy

        14.3.2. Dual Therapy

    14.4. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

        14.4.1. Oral

        14.4.2. Injectable

    14.5. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

        14.5.1. Women

        14.5.2. Men

    14.6. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

        14.6.1. Hospital Pharmacies

        14.6.2. Retail Pharmacies

        14.6.3. Online Pharmacies

        14.6.4. Others

    14.7. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027

        14.7.1. China

        14.7.2. Japan

        14.7.3. India

        14.7.4. Australia & New Zealand

        14.7.5. Rest of Asia Pacific

    14.8. Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis 

        14.8.1. By Gonococcal Infection Type

        14.8.2. By Treatment 

        14.8.3. By Route of Administration

        14.8.4. By Gender

        14.8.5. By Distribution Channel

        14.8.6. By Country/Sub-region

15. Latin America Gonorrhea Therapeutics Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Latin America Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

        15.2.1. Uncomplicated Gonococcal Infection

        15.2.2. Gonococcal Arthritis

        15.2.3. Gonococcal Meningitis and Endocarditis

    15.3. Latin America Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

        15.3.1. Monotherapy

        15.3.2. Dual Therapy

    15.4. Latin America Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

        15.4.1. Oral

        15.4.2. Injectable

    15.5. Latin America Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

        15.5.1. Women

        15.5.2. Men

    15.6. Latin America Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

        15.6.1. Hospital Pharmacies

        15.6.2. Retail Pharmacies

        15.6.3. Online Pharmacies

        15.6.4. Others

    15.7. Latin America Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027

        15.7.1. Brazil

        15.7.2. Mexico

        15.7.3. Rest of Latin America

    15.8. Latin America Gonorrhea Therapeutics Market Attractiveness Analysis 

        15.8.1. By Gonococcal Infection Type

        15.8.2. By Treatment 

        15.8.3. By Route of Administration

        15.8.4. By Gender

        15.8.5. By Distribution Channel

        15.8.6. By Country/Sub-region

16. Middle East & Africa Gonorrhea Therapeutics Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027

        16.2.1. Uncomplicated Gonococcal Infection

        16.2.2. Gonococcal Arthritis

        16.2.3. Gonococcal Meningitis and Endocarditis

    16.3. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027

        16.3.1. . Monotherapy

        16.3.2. Dual Therapy

    16.4. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027

        16.4.1. Oral

        16.4.2. Injectable

    16.5. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027

        16.5.1. Women

        16.5.2. Men

    16.6. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027

        16.6.1. Hospital Pharmacies

        16.6.2. Retail Pharmacies

        16.6.3. Online Pharmacies

        16.6.4. Others

    16.7. Middle East & Africa Gonorrhea Therapeutics Market Forecast by Country/Sub-region, 2017–2027

        16.7.1. GCC Countries

        16.7.2. South Africa

        16.7.3. Israel

        16.7.4. Rest of Middle East & Africa

    16.8. Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis 

        16.8.1. By Gonococcal Infection Type

        16.8.2. By Treatment 

        16.8.3. By Route of Administration

        16.8.4. By Gender

        16.8.5. By Distribution Channel

        16.8.6. By Country/Sub-region

17. Competition Landscape

    17.1. Market Player – Competition Matrix (by Tier and Size of companies)

    17.2. Market Share Analysis by Company (2018)

    17.3. Company Profiles

        17.3.1. GlaxoSmithKline plc. 

                  17.3.1.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.1.2 Financial Overview

                  17.3.1.3 SWOT Analysis

                  17.3.1.4 Strategic Overview

        17.3.2. Merck & Co., Inc.

                  17.3.2.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.2.2 Financial Overview

                  17.3.2.3 SWOT Analysis

                  17.3.2.4 Strategic Overview

        17.3.3. Pfizer Inc.

                  17.3.3.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.3.2 Financial Overview

                  17.3.3.3 SWOT Analysis

                  17.3.3.4 Strategic Overview

        17.3.4. AstraZeneca 

                  17.3.4.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.4.2 Financial Overview

                  17.3.4.3 SWOT Analysis

                  17.3.4.4 Strategic Overview

        17.3.5. Hologic, Inc. 

                  17.3.5.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.5.2 Financial Overview

                  17.3.5.3 SWOT Analysis

                  17.3.5.4 Strategic Overview

        17.3.6. Danaher

                  17.3.6.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.6.2 Financial Overview

                  17.3.6.3 SWOT Analysis

                  17.3.6.4 Strategic Overview

        17.3.7. Abbott

                  17.3.7.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.7.2 Financial Overview

                  17.3.7.3 SWOT Analysis

                  17.3.7.4 Strategic Overview

        17.3.8. Becton Dickinson and Company

                  17.3.8.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.8.2 Financial Overview

                  17.3.8.3 SWOT Analysis

                  17.3.8.4 Strategic Overview

        17.3.9. F. Hoffmann-La Roche Ltd

                  17.3.9.1 Company Overview (Headquarters, Business Segments, Employee Strength)

                  17.3.9.2 Financial Overview

                  17.3.9.3 SWOT Analysis

                  17.3.9.4 Strategic Overview

        17.3.10. Other Prominent Key Players

*Note: Financial details for companies that do not report this information in public domain might not be captured.

List of Tables

Table 1: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 2: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 3: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 4: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 5: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 6: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 7: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 8: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 9: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 10: North America  Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 11: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 12: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 13: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 14: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 15: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 17: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 18: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 19: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 20: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 21: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 22: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 23: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 24: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 25: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 26: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 27: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 28: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 29: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 30: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures 

 

Figure 1: Market Size, by Test Type (US$ Mn), 2018

Figure 2: Market Share, Top Trends, by Product Type

Figure 3: Global Gonorrhea Therapeutics Market Size (US$ Mn) and Forecast, 2018–2027

Figure 4: Global Gonorrhea Therapeutics Market Value Share, by Gonococcal Infection (2018)

Figure 5: Global Gonorrhea Therapeutics Market Value Share, by Treatment (2018)

Figure 6: Global Gonorrhea Therapeutics Market Value Share, by Route of Administration (2018)

Figure 7: Global Gonorrhea Therapeutics Market Value Share, by Gender (2018)

Figure 8: Global Gonorrhea Therapeutics Market Value Share, by Distribution Channel (2018)

Figure 9: Global Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

Figure 10: Global  Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Uncomplicated Gonococcal Infection, 2017–2027

Figure 11: Global  Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Gonococcal Arthritis, 2017–2027

Figure 12: Global  Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Gonococcal Meningitis and Endocarditis, 2017–2027

Figure 13: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2019–2027

Figure 14: Global Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 15: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Monotherapy, 2017–2027

Figure 16: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Dual Therapy, 2017–2027

Figure 17: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 18: Global Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 19: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 20: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Injectable 2017–2027

Figure 21: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 22: Global Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

Figure 23: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Women, 2017–2027

Figure 24: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Men 2017–2027

Figure 25: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2019–2027

Figure 26: Global Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 27: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 28: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 29: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 30: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 31: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 32: Global Gonorrhea Therapeutics Market Value Share Analysis, by Region, 2018 and 2027

Figure 33: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Region, 2019–2027

Figure 34: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

Figure 35: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

Figure 36: North America Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

Figure 37: North America Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 38: North America Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 39: North America Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

Figure 40: North America Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 41: North America Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

Figure 42: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

Figure 43: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

Figure 44: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

Figure 45: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

Figure 46: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

Figure 47: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

Figure 48: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

Figure 49: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

Figure 50: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 51: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 52: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

Figure 53: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 54: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

Figure 55: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

Figure 56: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

Figure 57: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

Figure 58: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

Figure 59: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

Figure 60: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

Figure 61: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

Figure 62: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

Figure 63: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 64: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 65: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

Figure 66: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 67: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

Figure 68: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

Figure 69: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

Figure 70: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

Figure 71: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

Figure 72: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

Figure 73: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

Figure 74: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027

Figure 75: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

Figure 76: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 77: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 78: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

Figure 79: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 80: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

Figure 81: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

Figure 82: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

Figure 83: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

Figure 84: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

Figure 85: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

Figure 86: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

Figure 87: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2018–2027

Figure 88: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027

Figure 89: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 90: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 91: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027

Figure 92: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 93: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027

Figure 94: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027

Figure 95: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027

Figure 96: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027

Figure 97: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027

Figure 98: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

798

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved